With the evolution of AMNOG-regulations, Germany has emerged as one of the most complex healthcare markets globally from a pricing and market access (P&MA) perspective. While Orphan Drugs (ODs) currently receive certain protections under the AMNOG framework, ongoing health policy debates are raising questions about the potential restriction or elimination of these OD-specific privileges. What would such changes mean for the German healthcare market and the accessibility of these critical therapies?
Access our webinar recording to explore:
- Current OD-regulation landscape within AMNOG and its vital role for P&MA
- Results of a P&MA simulation for the German OD-market without OD-regulation
- Resulting risk of market withdrawals across different therapeutic areas
- Strategic recommendations to optimize P&MA success for ODs in Germany
You will gain actionable insights to prepare your organization for potential regulatory shifts in the P&MA environment for ODs and support patient access to these essential therapies.
